Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep investors engaged” over the next 12-24 months and while Eylea-HD, or high dose, is “off to a good start,” standard Eylea headwinds could lead to declining franchise growth, the analyst tells investors.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces new, updated data from hematology pipeline at ASH
- Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
- Regeneron, Sanofi announce EC approval for Dupixent
- Regeneron price target lowered to $1,126 from $1,137 at Truist
- Regeneron price target lowered to $1,215 from $1,260 at RBC Capital